



## CERTIFICATION

I, JANICE R. ONG, Corporate Secretary and a duly authorized representative of EURO-MED LABORATORIES PHIL., INC., (the "Company") with SEC Registration Number 148022, and principal office at PPL Building, United Nations Avenue corner San Marcelino Street, Manila, do hereby certify and state that:

1. The Company will comply with the guidelines for the alternative filing of reports and documents through the Philippine Stock Exchange Electronic Disclosure Generation Technology ("PSE EDGE") and the Securities and Exchange Commission ("SEC") Markets and Securities Regulation Department in light of the imposition of the General Community Quarantine to prevent the spread of the 2019 Coronavirus Disease.
2. To the best of my knowledge, the information contained in the 17-C Report (Integrated Annual Corporate Governance Report for year 2019) are true and correct.
3. On behalf of the Company, I undertake to a) submit hard or physical copies of the 17-C Report (Integrated Annual Corporate Governance Report for year 2019); b) pay the filing fees; c) pay the penalties due (where applicable); and d) pay other impositions (where applicable), within the period to be allotted by the SEC for the submission of materials and payment of fees.
4. I am fully aware that non-submission of the physical copies of the materials as well as of a certification that such physical copies and those submitted via email refer to one and the same document, within the period to be allotted by the SEC for the submission of the materials, shall invalidate the Report and related applications, compliances, requests and other documents submitted through PSE EDGE.
5. I am executing this certification to attest to the truthfulness of the foregoing facts and for whatever legal purpose it may serve.

Executed this 24<sup>th</sup> day of July 2020.



JANICE R. ONG  
Corporate Secretary  
Passport No. EC6341484  
Date Issued 07 January 2016  
Valid Until 06 January 2021



SECURITIES AND EXCHANGE COMMISSION

SEC FORM 17-C

CURRENT REPORT UNDER SECTION 17  
OF THE SECURITIES REGULATION CODE  
AND SRC RULE 17.2(c) THEREUNDER

1. **24 July 2020**  
Date of Report (Date of earliest event reported)
2. SEC Identification Number **148022**      3. BIR Tax Identification No. **360-000-288-655-V**
4. **EURO-MED LABORATORIES PHIL, INC.**  
Exact name of registrant as specified in its charter
5. **Metro Manila, Philippines**.....  (SEC Use Only)  
Province, country or other jurisdiction of      Industry Classification Code:  
incorporation
7. **PPL Bldg., 1000 United Nations Avenue corner San Marcelino St., Manila 1000**  
Address of principal office      Postal Code
8. **63-2-8524-0091 to 98**  
Registrant's telephone number, including area code
9. Not Applicable  
Former name or former address, if changed since last report
10. Securities registered pursuant to Sections 8 and 12 of the SRC or Sections 4 and 8 of the RSA

Title of Each Class	Number of Shares of Common Stock Outstanding and Amount of Debt Outstanding
<b>Common Stock</b>	<b>4,112,140,540 shares</b>

11. Indicate the item numbers reported herein:

Item 9. Other Events : **INTEGRATED ANNUAL CORPORATE GOVERNANCE REPORT (I-ACGR)**

Pursuant to SEC Memorandum Circular No. 15, Series of 2017, enclosed herewith is the Integrated Annual Corporate Governance Report of the Company for the year 2019 duly notarized and signed by the required signatories.

Thank you.

**SIGNATURE**

Pursuant to the requirements of the Securities Regulation Code, Euro-Med Laboratories Phil., Inc. has duly caused this report to be signed on its behalf by the undersigned hereto duly authorized.

24 July 2020

**EURO-MED LABORATORIES PHIL., INC.**

By : 

**JANICE R. ONG**  
Corporate Secretary &  
Investment Relations Officer



## SEC FORM – I - ACGR

### INTEGRATED ANNUAL CORPORATE GOVERNANCE REPORT

1. Report is Filed for the Year 2019
2. SEC Identification Number 148022
3. BIR Tax Identification Number 000-288-655-000
4. Exact Name of Issuer as Specified in its Charter EURO-MED LABORATORIES PHIL., INC.
5. Metro Manila  
Province, Country or other jurisdiction of  
Incorporation or organization
6.  (SEC Use Only)  
Industry Classification Code
7. PPL Building, 1000 United Nations Avenue corner San Marcelino St., Manila 1007  
Address of Principal Office Postal Code
8. (02) 85240091 - 98  
Issuer's Telephone number, including area code
9. N/A  
Former name, former address, and former fiscal year, if changed since last report

**INTEGRATED ANNUAL CORPORATE GOVERNANCE REPORT**

COMPLIANT/  
NON-  
COMPLIANT

ADDITIONAL INFORMATION

EXPLANATION

**The Board's Governance Responsibilities**

**Principle 1:** The company should be headed by a competent, working board to foster the long-term success of the corporation, and to sustain its competitiveness and profitability in a manner consistent with its corporate objectives and the long-term best interests of its shareholders and other stakeholders.

**Recommendation 1.1**

1. Board is composed of directors with collective working knowledge, experience or expertise that is relevant to the company's industry/sector.	compliant	Provide information or link/reference to a document containing information on the following:  1. Academic qualifications, industry knowledge, professional experience, expertise and relevant trainings of directors  2. Qualification standards for directors to facilitate the selection of potential nominees and to serve as benchmark for the evaluation of its performance	<ul style="list-style-type: none"> <li>• Company website – <a href="http://www.euromedlab.net">www.euromedlab.net</a></li> <li>• Information Statement</li> <li>• Annual Report</li> <li>• Revised Manual on Corporate Governance</li> </ul>
2. Board has an appropriate mix of competence and expertise.	compliant		<ul style="list-style-type: none"> <li>• Information Statement</li> <li>• Annual Report</li> <li>• Revised Manual on Corporate Governance</li> <li>• Diversity of Board Membership Policy</li> </ul>
3. Directors remain qualified for their positions individually and collectively to enable them to fulfill their roles and responsibilities and respond to the needs of the organization.	compliant		<ul style="list-style-type: none"> <li>• Revised Manual on Corporate Governance</li> </ul>

**Recommendation 1.2**

1. Board is composed of a majority of non-executive directors.	<b>compliant</b>	Identify or provide link/reference to a document identifying the directors and the type of their directorships	<ul style="list-style-type: none"> <li>• <b>Company website – <a href="http://www.euromedlab.net">www.euromedlab.net</a></b></li> <li>• <b>Information Statement</b></li> <li>• <b>Annual Report</b></li> <li>• <b>Revised Manual on Corporate Governance</b></li> <li>• <b>Disclosure on the Results of the Organizational Meeting, 19 June 2019</b></li> </ul>
<b>Recommendation 1.3</b>			
1. Company provides in its Board Charter and Manual on Corporate Governance a policy on training of directors.	<b>compliant</b>	Provide link or reference to the company's Board Charter and Manual on Corporate Governance relating to its policy on training of directors.	<ul style="list-style-type: none"> <li>• <b>Company website – <a href="http://www.euromedlab.net">www.euromedlab.net</a></b></li> <li>• <b>Board Charter</b></li> <li>• <b>Revised Manual on Corporate Governance</b></li> <li>• <b>Corporate Governance and Nomination Committee Charter</b></li> </ul>
2. Company has an orientation program for first time directors.	<b>compliant</b>	Provide information or link/reference to a document containing information on the orientation program and trainings of directors for the previous year, including the number of hours attended and	<ul style="list-style-type: none"> <li>• <b>Board Charter</b></li> <li>• <b>Revised Manual on Corporate Governance</b></li> <li>• <b>Corporate Governance and Nomination Committee Charter</b></li> </ul>

<p>3. Company has relevant annual continuing training for all directors.</p>	<p><b>compliant</b></p>	<p>topics covered.</p>	<ul style="list-style-type: none"> <li>• Board Charter</li> <li>• Revised Manual on Corporate Governance</li> <li>• Corporate Governance and Nomination Committee Charter</li> <li>• Disclosure on the Certificates of Attendance for having attended the Annual Corporate Governance Training Program dated April 11, 2019, May 28, 2019, May 29, 2019, September 20, 2019, September 27, 2019 and Oct. 12, 2019 respectively.</li> </ul>
<p><b>Recommendation 1.4</b></p>			
<p>1. Board has a policy on board diversity.</p>	<p><b>compliant</b></p>	<p>Provide information on or link/reference to a document containing information on the company's board diversity policy.</p> <p>Indicate gender composition of the board.</p>	<ul style="list-style-type: none"> <li>• Diversity of Board Membership Policy</li> <li>• Corporate Governance and Nomination Committee Charter</li> <li>• Board is composed of 3 females and 7 males, to wit : <ul style="list-style-type: none"> <li>✚ Esperanza I. Cabral, M.D.</li> <li>✚ Evangeline V. Baviera, M.D.</li> <li>✚ Mrs. Georgiana S. Evidente</li> <li>✚ Dr. William G. Padolina</li> <li>✚ Mr. Edwin D. Felst</li> <li>✚ Mr. Basilio C. Yap</li> <li>✚ Dr. Johnny C. Yap</li> <li>✚ Atty. Francis Y. Gaw</li> <li>✚ Mr. Basilio C. Yap</li> <li>✚ Mr. Michael Vincent Y. Yap (resigned effective November 26, 2019 to pursue Master's Degree abroad)</li> </ul> </li> </ul>
<p><b>Optional: Recommendation 1.4</b></p>			

